Carter Gould
Stock Analyst at Cantor Fitzgerald
(2.52)
# 2,264
Out of 4,876 analysts
205
Total ratings
47.93%
Success rate
-0.15%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Reiterates: Neutral | $305 | $280.71 | +8.65% | 17 | Jun 24, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $535 | $443.88 | +20.53% | 3 | May 6, 2025 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Neutral | $55 | $46.84 | +17.43% | 16 | Apr 23, 2025 | |
| REGN Regeneron Pharmaceuticals | Assumes: Overweight | $695 | $527.48 | +31.76% | 20 | Apr 22, 2025 | |
| PFE Pfizer | Initiates: Neutral | $24 | $24.38 | -1.56% | 15 | Apr 22, 2025 | |
| PCVX Vaxcyte | Initiates: Overweight | n/a | $33.12 | - | 1 | Apr 22, 2025 | |
| MRK Merck & Co. | Initiates: Neutral | $85 | $79.26 | +7.24% | 11 | Apr 22, 2025 | |
| LLY Eli Lilly and Company | Initiates: Overweight | $975 | $784.71 | +24.25% | 12 | Apr 22, 2025 | |
| GILD Gilead Sciences | Assumes: Overweight | $125 | $109.22 | +14.45% | 15 | Apr 22, 2025 | |
| ABBV AbbVie | Initiates: Overweight | $210 | $186.46 | +12.62% | 15 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $160 → $165 | $126.31 | +30.63% | 12 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $14.91 | +34.14% | 6 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $190 → $180 | $127.62 | +41.04% | 24 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $100 | $79.92 | +25.13% | 1 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $3 | $1.10 | +172.73% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3 | $0.90 | +232.59% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $1.51 | +496.03% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $95 | $33.62 | +182.57% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $20 | $16.38 | +22.14% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $73 | $64.83 | +12.60% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $1.47 | +719.11% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $1.5 | $1.26 | +19.05% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $2.25 | $0.37 | +510.25% | 4 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $392 → $380 | $227.21 | +67.25% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 → $82 | $69.99 | +17.16% | 5 | Jan 16, 2019 |
Amgen
Jun 24, 2025
Reiterates: Neutral
Price Target: $305
Current: $280.71
Upside: +8.65%
Vertex Pharmaceuticals
May 6, 2025
Reiterates: Overweight
Price Target: $535
Current: $443.88
Upside: +20.53%
Bristol-Myers Squibb Company
Apr 23, 2025
Reiterates: Neutral
Price Target: $55
Current: $46.84
Upside: +17.43%
Regeneron Pharmaceuticals
Apr 22, 2025
Assumes: Overweight
Price Target: $695
Current: $527.48
Upside: +31.76%
Pfizer
Apr 22, 2025
Initiates: Neutral
Price Target: $24
Current: $24.38
Upside: -1.56%
Vaxcyte
Apr 22, 2025
Initiates: Overweight
Price Target: n/a
Current: $33.12
Upside: -
Merck & Co.
Apr 22, 2025
Initiates: Neutral
Price Target: $85
Current: $79.26
Upside: +7.24%
Eli Lilly and Company
Apr 22, 2025
Initiates: Overweight
Price Target: $975
Current: $784.71
Upside: +24.25%
Gilead Sciences
Apr 22, 2025
Assumes: Overweight
Price Target: $125
Current: $109.22
Upside: +14.45%
AbbVie
Apr 22, 2025
Initiates: Overweight
Price Target: $210
Current: $186.46
Upside: +12.62%
Dec 23, 2024
Maintains: Overweight
Price Target: $160 → $165
Current: $126.31
Upside: +30.63%
Nov 1, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $14.91
Upside: +34.14%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $190 → $180
Current: $127.62
Upside: +41.04%
Aug 29, 2024
Initiates: Overweight
Price Target: $100
Current: $79.92
Upside: +25.13%
Aug 14, 2024
Maintains: Overweight
Price Target: $10 → $3
Current: $1.10
Upside: +172.73%
Jun 13, 2024
Maintains: Overweight
Price Target: $7 → $3
Current: $0.90
Upside: +232.59%
Jun 11, 2024
Initiates: Overweight
Price Target: $9
Current: $1.51
Upside: +496.03%
May 23, 2024
Maintains: Overweight
Price Target: $100 → $95
Current: $33.62
Upside: +182.57%
Apr 16, 2024
Maintains: Overweight
Price Target: $25 → $20
Current: $16.38
Upside: +22.14%
Feb 29, 2024
Maintains: Overweight
Price Target: $62 → $73
Current: $64.83
Upside: +12.60%
May 5, 2023
Maintains: Overweight
Price Target: $14 → $12
Current: $1.47
Upside: +719.11%
Mar 21, 2023
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $1.26
Upside: +19.05%
Aug 16, 2022
Maintains: Equal-Weight
Price Target: $2.5 → $2.25
Current: $0.37
Upside: +510.25%
Jan 20, 2022
Maintains: Equal-Weight
Price Target: $392 → $380
Current: $227.21
Upside: +67.25%
Jan 16, 2019
Downgrades: Neutral
Price Target: $75 → $82
Current: $69.99
Upside: +17.16%